An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
(CheckMate 800 Trial)
Recruiting in Palo Alto (17 mi)
+10 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Bristol-Myers Squibb
No Placebo Group
Prior Safety Data
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?
The purpose of this study is to evaluate safety and efficacy of different administration regimens of nivolumab plus ipilimumab in subjects with renal cell carcinoma.
Eligibility Criteria
Inclusion Criteria
Must have at least 1 lesion with measurable disease
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Advanced Renal Cell Carcinoma
See 1 more
Treatment Details
Interventions
- Opdivo (Checkpoint Inhibitor)
- Yervoy (Checkpoint Inhibitor)
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Sequential AdministrationExperimental Treatment2 Interventions
Nivolumab and Ipilimumab Sequential Administration
Group II: Co-AdministrationExperimental Treatment2 Interventions
Nivolumab and Ipilimumab Co-Administration
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Local InstitutionPittsburgh, PA
Cancer Specialists of North FLJacksonville, FL
University Of Iowa Hospitals And ClinicsIowa City, IA
Levine Cancer InstituteCharlotte, NC
Loading ...
Who Is Running the Clinical Trial?
Bristol-Myers SquibbLead Sponsor